Global Statistics Representing Hematology Diagnostics Market Scenario
Hematology includes treatment of blood disorders and malignancies such as hemophilia, leukemia, lymphoma and sickle-cell anemia. Increasing incidences of blood disorders such as leukemia, lymphoma and sickle-cell are key factors contributing to driving the global hematology diagnostics market during the forecast period 2019–2026. According to the Centers for Disease Control and Prevention, sickle cell disease affects millions of people throughout the globe each year. Use of hematology diagnostics has increased due to rising aging population, technological improvements, and growing demand for improved healthcare facilities. Additionally, increasing government regulations to support healthcare infrastructure is also propelling the growth of the market. Moreover, hematology diagnostic devices are expected to rise due to increasing support from different private and government organizations.
The growth in POCT in developed economies, improvement in technology leading to easy usage, and ultrasensitive method with dynamic range of tests is boosting the growth of the market. For instance, in May 2018, Beckman Coulter Diagnostics launched a next-generation software to support new and existing DxH 500 hematology analyzers.
The global hematology diagnostics market was valued around USD 6,200 million in 2017 and is anticipated to expand at a CAGR of 6.2 % over the forecast period.
The global hematology diagnostic market is segmented by product type, test, end-user, and region.
On the basis of product type, the market is segmented into hematology analyzer, flow cytometers, and consumables. The hematology analyzer is further sub-segmented into fully-automated hematology analyzers and semi-automated hematology analyzers. Whereas, consumable segment is sub-segmented into reagents, stains, controls & calibrators, and others. Consumables segmented is expected to dominate over the forecast period. This significant growth is attributed to rise in diagnosis of blood disorders and other infections. Rising awareness and early detection are also fueling growth of the segment.
Based on the test, the market is segmented into anemia, hemoglobinopathy, leukemia/lymphoma phenotyping, hematology pathophysiology, complete blood count (CBC), and others.
On the basis end-user, the market is segmented into hospital laboratories, commercial, service providers, government reference laboratories, research and academic institutes,
Others. Diagnostic labs segment is expected to hold the major share of the market. This is attributed to increasing number of diagnostic centers and availability of advanced instruments. Furthermore, automation of diagnostic instruments is estimated to reduce the cost of these tests and thus, propelling the demand of the market
The global hematology diagnostic market is divided into four major regions such as North America, Europe, Asia Pacific (APAC), and Latin America and Middle East & Africa (LAMEA).
North America is expected to dominate the global hematology diagnostic market owing to increasing rate of patients suffering from blood disorders such as sickle cell anemia, thalassemia, leukemia and others. According to the Centers for Disease Control and Prevention, it was estimated that approximately 100,000 Americans are affected by sickle cell anemia. Increasing prevalence of target diseases and growing demand for blood transfusion results is influencing demand for hematology testing.
Europe is expected to witness strong growth during the forecasted period owing to the rising prevalence of blood disorder and increasing healthcare expenditure. The growing manufacturer which mainly focus on business expansion is driving the market in this region. Players are constantly developing advanced products for hematology diagnostics and entering into distribution agreements is strengthen the growth of the market in Europe. Moreover, increasing prevalence of leukemia is growing hematology diagnostic market. For instance, according to cancer research U.K. in 2015, approximately 3% people suffered from leukemia in U. K.
Asia Pacific (APAC) is expected to be fastest growing region during the forecast period 2019–2026. This is attributed to improving the healthcare infrastructure and increasing number of the incidence of hematological diseases are driving the market especially in the countries such as China and India.
LAMEA is expecting a steady growth owing to lack of awareness and high price of treatment is slowing the market in this region.
Some of the players in the global hematology diagnostics market include Sysmex (Japan), Danaher (U.S.), Nihon Kohden (Japan), Siemens (Germany), Abbott Laboratories (U.S.), Boule Diagnostics (Sweden), HORIBA (Japan), Bio-Rad Laboratories (US), BioSystems (Spain), Diatron (Hungary), Drew Scientific (U.S.), EKF Diagnostics (U.K), Mindray (China), Ortho Clinical Diagnostics (U.S.), and Roche (Switzerland)
Hematology Diagnostics Market Segmentation
By Product Type
Why buy this report right now?
Our report covers hematology diagnostic market insights, focusing on recent development in the market in different region and development strategies of the companies. Moreover, following sections are specifically covered in the report.
• Definitive Market Data
• Hematology diagnostic market Analysis
• Competitive Analysis
• Recent Opportunities in the Market
• 6-7 year performance forecasts: major segments covering top product type, end-user application, and geographies
• Market Share Analysis
• Potential Venture Avenues